You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CLINICAL TRIALS PROFILE FOR DIBENZYLINE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for DIBENZYLINE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00569855 ↗ Intravenous Phenoxybenzamine Use in Pediatric Patients Undergoing Open-Heart Surgery Completed Arkansas Children's Hospital Research Institute Phase 2 2001-02-01 Cardiopulmonary bypass is done with a machine that does the work of the heart and lungs during open-heart surgery. This study is to determine if intravenous (i.v.) phenoxybenzamine is safe. This drug lowers the blood pressure, making it easier for the cardiopulmonary bypass machine to deliver blood and oxygen to all of the organs and tissues.
NCT00569855 ↗ Intravenous Phenoxybenzamine Use in Pediatric Patients Undergoing Open-Heart Surgery Completed University of Arkansas Phase 2 2001-02-01 Cardiopulmonary bypass is done with a machine that does the work of the heart and lungs during open-heart surgery. This study is to determine if intravenous (i.v.) phenoxybenzamine is safe. This drug lowers the blood pressure, making it easier for the cardiopulmonary bypass machine to deliver blood and oxygen to all of the organs and tissues.
NCT00620945 ↗ Use of Phenoxybenzamine [PBZ] IV to Assist High Flow Low Pressure Perfusion [HFLPP] on Cardio-pulmonary Bypass Terminated The Cleveland Clinic N/A 2006-06-01 Cardiopulmonary bypass [CPB] in small size bodies can result in decreased peripheral perfusion. This results in anaerobic metabolism as evidenced by lactic acidosis. High flow perfusion results in systemic hypertension which is accentuated by moderate hypothermia commonly used during cardiopulmonary bypass. Phenoxybenzamine [PBZ] is an arteriolar vasodilator that acts by irreversibly blocking the alpha adrenergic receptors. It causes vasodilatation allowing high flow, low pressure CPB. It has been used extensively outside US in Canada, Europe and Australia. In the US oral PBZ is FDA approved, whereas intravenous PBZ is only available as an investigational drug
NCT00770705 ↗ Parenteral Phenoxybenzamine During Congenital Heart Disease Surgery Withdrawn Vanderbilt University Phase 2 2008-10-01 Phenoxybenzamine, an irreversible alpha-adrenergic blocker, may prove beneficial to infants and children with congenital heart disease undergoing open cardiac repair, due to a theoretic benefits of a uniform and smooth reduction in systemic vascular resistance in the perioperative period. Vasodilation allows for low pressure, high flow systemic perfusion while on cardiopulmonary bypass. Support for the use of phenoxybenzamine in humans has been documented in several studies involving the perioperative management of both adults and children requiring cardiopulmonary bypass, and in management of patients with pheochromocytoma. 1-7 Phenoxybenzamine has been associated with more uniform body cooling and rewarming, and improved tissue perfusion during bypass.8 It is also known to increase cardiac output, stroke volume, and renal blood flow when given intravenously. 9 Specifically in pediatric open heart surgery, the combined use of phenoxybenzamine and dopamine provided a stable hemodynamic condition without a high total peripheral vascular resistance and stimulated postoperative diuresis. 9 Afterload reduction with parenteral phenoxybenzamine in neonates undergoing the Norwood procedure for hypoplastic left heart syndrome is associated with improved systemic oxygen delivery and stabilization of systemic vascular resistance.10 Furthermore, a strategy of reducing afterload with phenoxybenzamine and stabilizing the pulmonary to systemic flow ratio in this select population of patients has also been shown to improve operative survival. 11 We hypothesize that phenoxybenzamine will reduce afterload on the systemic ventricle in our selected patient population, thereby improving ventricular performance and decreasing the risks of pulmonary to systemic flow imbalance associated with current short-acting vasodilator therapy. We will plan to evaluate both physiologic variables as well as surgical outcomes in the selected study population.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for DIBENZYLINE

Condition Name

Condition Name for DIBENZYLINE
Intervention Trials
Cardiopulmonary Bypass 2
Congenital Heart Disease 1
Congenital Heart Surgery 1
Open-heart Surgery 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for DIBENZYLINE
Intervention Trials
Heart Diseases 1
Heart Defects, Congenital 1
Urinary Retention 1
Pheochromocytoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for DIBENZYLINE

Trials by Country

Trials by Country for DIBENZYLINE
Location Trials
United States 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for DIBENZYLINE
Location Trials
Illinois 1
California 1
Tennessee 1
Ohio 1
Arkansas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for DIBENZYLINE

Clinical Trial Phase

Clinical Trial Phase for DIBENZYLINE
Clinical Trial Phase Trials
Phase 3 2
Phase 2 2
N/A 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for DIBENZYLINE
Clinical Trial Phase Trials
Terminated 1
Completed 1
Withdrawn 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for DIBENZYLINE

Sponsor Name

Sponsor Name for DIBENZYLINE
Sponsor Trials
Arkansas Children's Hospital Research Institute 1
University of Arkansas 1
The Cleveland Clinic 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for DIBENZYLINE
Sponsor Trials
Other 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.